You are here

BeiGene

Say goodbye to BeiGene as the oncology biopharma becomes BeOne Medicines in rebrand

Fierce Pharma

Thu, 11/14/24 - 11:06 am

BeOne Medicines

BeiGene, ex-AstraZeneca exec faces investigation in China: reports

Fierce Pharma

Fri, 10/25/24 - 11:40 am

AbbVie sues rival BeiGene over alleged theft of cancer therapy secrets

Reuters

Tue, 09/10/24 - 09:15 am

FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds

Fierce Pharma

Fri, 08/23/24 - 10:55 am

Bristol Myers Squibb

BeiGene debuts $800M biologics plant set to create ‘hundreds’ of jobs in New Jersey

Fierce Pharma

Tue, 07/23/24 - 06:33 pm

drug manufacturing

[podcast]Brukinsa approval raises BeiGene’s hematology profile

Medical Marketing and Media

Wed, 03/20/24 - 09:38 pm

FDA approves expanded use of BeiGene's blood cancer drug

Reuters

Thu, 03/7/24 - 05:30 pm

BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor

BioSpace

Tue, 11/21/23 - 11:54 am

BeiGene to go solo with cancer drug after Novartis deal termination

Yahoo/Reuters

Tue, 09/19/23 - 10:30 am

Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban

Fierce Pharma

Thu, 08/3/23 - 11:22 am

Bristol Myers Squibb

Novartis retreats from TIGIT, handing $300M candidate back to BeiGene

Fierce Biotech

Tue, 07/11/23 - 10:22 am

AbbVie's Imbruvica-Brukinsa patent suit may have merit, and BeiGene will likely settle: expert

Fierce Pharma

Tue, 06/27/23 - 10:21 pm

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

Fierce Pharma

Fri, 06/16/23 - 09:44 am

BeiGene's gastric cancer drug succeeds in late-stage trial

Reuters

Thu, 04/20/23 - 11:41 am

clinical trials

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint

NJ Business

Wed, 03/22/23 - 11:12 am

drug manufacturing

BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse

Fierce Biotech

Fri, 03/17/23 - 09:55 am

immuno-oncology

Leap Therapeutics

Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report

Fierce Biotech

Sun, 03/5/23 - 03:06 pm

Moderna Therapeutics

Gilead Sciences

BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches

Fierce Pharma

Mon, 02/27/23 - 07:06 pm

This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more

RAPS.org

Sun, 01/22/23 - 01:00 pm

clinical trials

clinicaltrials.gov

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

Endpoints

Thu, 01/19/23 - 08:55 pm

Pages